Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Tenaya Therapeutics (NASDAQ:TNYA) but lowers the price target from $19 to $18.

March 20, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Tenaya Therapeutics but lowers the price target from $19 to $18.
While the reduction in price target from $19 to $18 by Canaccord Genuity could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Whitney Ijem suggests a continued positive outlook on Tenaya Therapeutics. The impact on the stock price is likely neutral in the short term as the lowered price target is offset by the reaffirmed confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100